Open AccessThe New Molecules Are Changing the Course of Pediatric Chronically Active Ulcerative Colitis
Author(s) -
MartínMasot Rafael,
Ortiz Pérez Pilar,
Torcuato Rubio Encarnación,
Blasco Alonso Javier,
Herrador López Marta,
Gallego Fernández Carmen,
NavasLópez Víctor Manuel
Publication year - 2021
Publication title -
jpgn reports
Language(s) - English
Resource type - Journals
ISSN - 2691-171X
DOI - 10.1097/pg9.0000000000000100
Subject(s) - ulcerative colitis , medicine , tofacitinib , vedolizumab , ustekinumab , multidisciplinary team , intensive care medicine , disease , therapeutic approach , medical therapy , surgery , adalimumab , rheumatoid arthritis , nursing
Chronically active ulcerative colitis (UC) constitutes a challenge in an era where medical therapeutic options have increased while experience with colectomies has decreased. The change in the therapeutic paradigm of the disease means that patients with chronically active UC are being managed waiting to find their therapeutic target. We present 2 cases of children with chronically active UC who did not respond to intravenous steroids nor sequential therapy. A response was obtained with ustekinumab and tofacitinib, 2 drugs widely used in adults but still with little evidence in children. Highlighting the important role of patients and their families helped decision‐making, facilitating the work of the medical team. With multidisciplinary management and close follow‐up, they have been able to avoid surgery entering complete clinical remission.